Financials of Glenmark Pharmaceuticals Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Financials of Glenmark Pharmaceuticals Ltd

Quarterly Results

Quarter-by-quarter operating performance

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales +3,1003,0013,0363,2072,5073,0633,2443,4343,3883,2563,2646,0473,901
Expenses +2,6262,6032,5992,7452,7152,5592,6562,8322,7872,6952,6843,6873,031
Operating Profit474398437462-2095045886026005615812,360870
OPM %15%13%14%14%-8%16%18%18%18%17%18%39%22%
Other Income +209-696-32-20587351313931-361-297-1,184-140
Interest9710911212113414940485267586641
Depreciation152135142141147151118120123125130141154
Profit before tax435-542151-6-403555462473456896967534
Tax %33%-26%-14%997%-18%319%26%25%24%45%51%37%24%
Net Profit +291-403173-62-331-1,214340354348447610403
EPS in Rs9.66-15.185.31-2.90-12.45-43.1712.0612.5512.330.161.6621.6314.29

Financials of Glenmark Pharmaceuticals Ltd

Profit & Loss

Annual income statement trend

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales +6,0056,5637,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,468
Expenses +4,9145,3486,1257,0437,4578,2808,9428,8609,9789,94810,61810,97012,097
Operating Profit1,0911,2141,4372,0371,6171,5861,6992,0842,3271,6351,1952,3514,371
OPM %18%18%19%22%18%16%16%19%19%14%10%18%27%
Other Income +11-18020-448937519195-101-10336-259-1,982
Interest189190179237286335377353298349516207233
Depreciation217300234264302326417444487569582486551
Profit before tax6975441,0441,4911,1191,3011,0961,3821,4417074341,3991,605
Tax %22%61%29%26%28%29%29%30%31%47%430%25%
Net Profit +5462097431,109804925776970994377-1,4341,0471,065
EPS in Rs19.997.7226.3339.2928.4932.7827.5034.3833.3710.53-53.2237.1137.74
Dividend Payout %0%26%8%5%7%6%9%7%7%24%-5%7%

Financials of Glenmark Pharmaceuticals Ltd

Balance Sheet

Capital structure and asset base

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital27272828282828282828282828
Reserves2,9561,7563,6014,4645,1355,5776,0427,0369,0589,4467,8208,8219,554
Borrowings +3,2673,8003,9884,7244,6394,4494,8694,9863,9624,6081,2312,4731,224
Other Liabilities +2,1762,7262,5752,5482,7933,2353,7293,5244,0035,2895,2794,6698,196
Total Liabilities8,4278,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,002
Fixed Assets +3,0912,0152,5942,7553,0303,6705,0295,1295,8875,4224,2104,4875,210
CWIP54775437081,1221,3991,2221,3821,0101,190662835695
Investments01717161530252550457905642
Other Assets +5,3315,7997,0398,2858,4298,1908,3939,04010,10512,7158,69710,61313,054
Total Assets8,4278,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,002

Financials of Glenmark Pharmaceuticals Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity +8544823456571,6481,3241,3921,1311,109625-265-828
Cash from Investing Activity +-566-712-950-1,001-1,003-883-774-662-316-5154,38758
Cash from Financing Activity +-98199699543-468-739-445-442-520-77-3,906787
Net Cash Flow190-3193199177-297174282723221517
Free Cash Flow481-56-544-7662571261645632075-1,162-1,575
CFO/OP102%66%57%67%124%111%109%79%72%77%65%-6%

Financials of Glenmark Pharmaceuticals Ltd

Ratios

Working capital efficiency and return ratios

Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days1311401209794818386921155792
Inventory Days191247249299244244211230208203208254
Days Payable279379308243225241210226190172210216
Cash Conversion Cycle4386115211385849011014756129
Working Capital Days6247511259964546765141-244
ROCE %15%16%19%21%15%15%14%15%16%10%12%19%